OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CTEV$23.4759

Claritev Corp

Business Support ServicesVerified

Claritev Corp's capital structure is highly leveraged, with a debt-to-equity ratio of 3.87, indicating significant reliance on debt financing. The company's liquidity position is constrained, as evidenced by a current ratio of 0.98 and negative free cash flow of $463.27 million, which suggests that operating cash flow is insufficient to cover capital expenditures and other obligations. The price-to-book ratio of 0.34 indicates that the company's market value is significantly below its book value, potentially signaling undervaluation or financial distress. Profitability metrics for Claritev Corp are negative, with a return on equity of -46.11% and a return on assets of -8.48%, both of which are well below industry norms and indicate poor capital efficiency and operational performance. The company's operating income is negative at -$480.52 million, and net income is -$539.69 million, reflecting substantial losses that are not offset by gross profit of $174.43 million. Geographically and segment-wise, Claritev Corp's revenue concentration is not explicitly disclosed, but the company's primary activity is in the health care technology sector, which is part of the broader industrial services industry. The lack of detailed segment reporting limits the ability to assess geographic or product diversification risks. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. However, the negative operating and net income figures suggest a challenging operating environment, and the company's free cash flow position indicates a need for external financing to sustain operations. Analysts have provided a wide range of price targets, from $21.00 to $90.00, with a mean of $39.80 and a median of $28.00, reflecting significant uncertainty about the company's future performance. Risk factors for Claritev Corp include high leverage, negative free cash flow, and poor profitability, which collectively increase the company's vulnerability to economic downturns and operational disruptions. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's negative net cash position after subtracting total debt is a key flag. The company has not disclosed any recent events or filings that would provide additional insight into its strategic direction or operational changes.

30-day price · CTEV-3.19 (-18.7%)
Low$13.33High$31.70Close$13.87As of17 May, 00:00 UTC
Profile
CompanyClaritev Corp
TickerCTEV.K
SectorIndustrials
BusinessIndustrial & Commercial Services
Industry groupIndustrial & Commercial Services
IndustryBusiness Support Services
AI analysis

Business. Claritev Corp provides industrial services within the business support services industry, primarily generating revenue through its operations in the health care technology sector.

Classification. Claritev Corp is classified under the Industrials economic sector, Industrial & Commercial Services business sector, and Business Support Services industry, with a confidence level of 0.92.

Claritev Corp's capital structure is highly leveraged, with a debt-to-equity ratio of 3.87, indicating significant reliance on debt financing. The company's liquidity position is constrained, as evidenced by a current ratio of 0.98 and negative free cash flow of $463.27 million, which suggests that operating cash flow is insufficient to cover capital expenditures and other obligations. The price-to-book ratio of 0.34 indicates that the company's market value is significantly below its book value, potentially signaling undervaluation or financial distress. Profitability metrics for Claritev Corp are negative, with a return on equity of -46.11% and a return on assets of -8.48%, both of which are well below industry norms and indicate poor capital efficiency and operational performance. The company's operating income is negative at -$480.52 million, and net income is -$539.69 million, reflecting substantial losses that are not offset by gross profit of $174.43 million. Geographically and segment-wise, Claritev Corp's revenue concentration is not explicitly disclosed, but the company's primary activity is in the health care technology sector, which is part of the broader industrial services industry. The lack of detailed segment reporting limits the ability to assess geographic or product diversification risks. The company's growth trajectory is uncertain, with no specific revenue growth projections provided. However, the negative operating and net income figures suggest a challenging operating environment, and the company's free cash flow position indicates a need for external financing to sustain operations. Analysts have provided a wide range of price targets, from $21.00 to $90.00, with a mean of $39.80 and a median of $28.00, reflecting significant uncertainty about the company's future performance. Risk factors for Claritev Corp include high leverage, negative free cash flow, and poor profitability, which collectively increase the company's vulnerability to economic downturns and operational disruptions. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the company's negative net cash position after subtracting total debt is a key flag. The company has not disclosed any recent events or filings that would provide additional insight into its strategic direction or operational changes.
Key takeaways
  • Claritev Corp is highly leveraged with a debt-to-equity ratio of 3.87, indicating significant financial risk.
  • The company is experiencing substantial losses, with a net income of -$539.69 million and a return on equity of -46.11%.
  • Claritev Corp's liquidity position is weak, as evidenced by a current ratio of 0.98 and negative free cash flow of $463.27 million.
  • Analysts have provided a wide range of price targets, from $21.00 to $90.00, reflecting significant uncertainty about the company's future performance.
  • The company's valuation is significantly below book value, with a price-to-book ratio of 0.34.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's operating margin is negative, indicating a lack of profitability and potential for margin contraction.",
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$234.5M
Gross profit$174.4M
Operating income-$480.5M
Net income-$539.7M
R&D
SG&A
D&A
SBC
Operating cash flow$49.7M
CapEx-$30.5M
Free cash flow-$463.3M
Total assets$6.37B
Total liabilities$5.20B
Total equity$1.17B
Cash & equivalents$58.7M
Long-term debt$4.52B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.12B$370.3M$102.1M$429.5M
FY-3$1.08B-$328.2M-$572.9M-$253.4M
FY-2$961.5M$215.9M-$91.7M$219.5M
FY-1$930.6M-$1.45B-$1.65B-$1.33B
FY0$965.4M$20.1M-$284.3M$31.5M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$8.22B$2.34B$185.3M
FY-3$7.37B$1.79B$334.0M
FY-2$6.96B$1.71B$71.5M
FY-1$5.15B$84.0M$16.8M
FY0$4.89B-$173.9M$16.8M
PeriodOCFCapExFCFSBC
FY-4$404.7M-$84.6M$429.5M
FY-3$372.4M-$89.7M-$253.4M
FY-2$171.7M-$108.9M$219.5M
FY-1$107.6M-$118.1M-$1.33B
FY0$117.3M-$129.6M$31.5M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$234.5M-$480.5M-$539.7M-$463.3M
FQ-6$233.5M-$523.9M-$576.7M-$494.4M
FQ-5$230.5M-$338.2M-$391.4M-$314.6M
FQ-4$232.1M-$105.3M-$138.0M-$59.6M
FQ-3$231.3M$1.3M-$71.3M$332.0k
FQ-2$241.6M$16.5M-$62.6M$24.0M
FQ-1$246.0M$10.1M-$69.8M$6.0M
FQ0$246.6M-$7.8M-$80.6M$1.3M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$6.37B$1.17B$58.7M
FQ-6$5.74B$603.4M$48.8M
FQ-5$5.32B$207.6M$86.6M
FQ-4$5.15B$84.0M$16.8M
FQ-3$5.08B$14.8M$23.1M
FQ-2$5.07B-$39.9M$56.4M
FQ-1$4.99B-$101.8M$39.2M
FQ0$4.89B-$173.9M$16.8M
PeriodOCFCapExFCFSBC
FQ-7$49.7M-$30.5M-$463.3M
FQ-6$68.2M-$56.0M-$494.4M
FQ-5$141.0M-$87.7M-$314.6M
FQ-4$107.6M-$118.1M-$59.6M
FQ-3-$30.1M-$38.9M$332.0k
FQ-2$31.2M-$63.5M$24.0M
FQ-1$51.0M-$99.7M$6.0M
FQ0$117.3M-$129.6M$1.3M
Valuation
Market price$23.47
Market cap$398.2M
Enterprise value$4.86B
P/E
Reported non-GAAP P/E
EV/Revenue20.7
EV/Op income
EV/OCF97.8
P/B0.3
P/Tangible book0.3
Tangible book$1.17B
Net cash-$4.47B
Current ratio1.0
Debt/Equity3.9
ROA-8.5%
ROE-46.1%
Cash conversion-9.0%
CapEx/Revenue-13.0%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Industrial Services · cohort 626 companies
MetricCTEVActivity
Op margin-204.9%6.0% medp25 -2.1% · p75 13.4%bottom quartile
Net margin-230.1%4.1% medp25 -2.2% · p75 10.8%bottom quartile
Gross margin74.4%28.8% medp25 19.4% · p75 44.6%top quartile
R&D / revenue2.7% medp25 2.4% · p75 3.1%
CapEx / revenue-13.0%-5.0% medp25 -12.8% · p75 -1.9%bottom quartile
Debt / equity387.0%26.4% medp25 5.2% · p75 66.7%top quartile
Observations
IR observations
Mean price target39.80 USD
Median price target28.00 USD
High price target90.00 USD
Low price target21.00 USD
Mean recommendation1.80 (1=strong buy, 5=strong sell)
Strong-buy count2.00
Buy count2.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate-14.92 USD
Last actual EPS-17.30 USD
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-16 12:56 UTC#2d338dc1
Market quoteclose USD 26.55 · shares 0.02B diluted
no public URL
2026-05-16 12:56 UTC#aae09e58
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 17:23 UTCJob: d981babd